CN1625404A - 用于心血管疾病预防或治疗的醛甾酮受体拮抗剂和α－肾上腺素调节剂的组合治疗 - Google Patents

用于心血管疾病预防或治疗的醛甾酮受体拮抗剂和α－肾上腺素调节剂的组合治疗 Download PDF

Info

Publication number
CN1625404A
CN1625404A CNA03802988XA CN03802988A CN1625404A CN 1625404 A CN1625404 A CN 1625404A CN A03802988X A CNA03802988X A CN A03802988XA CN 03802988 A CN03802988 A CN 03802988A CN 1625404 A CN1625404 A CN 1625404A
Authority
CN
China
Prior art keywords
epoxy
epinephrine
regulator
receptor antagonist
aldosterone receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA03802988XA
Other languages
English (en)
Chinese (zh)
Inventor
埃伦·G·麦克马洪
埃米·E·鲁道夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PharMetrix Corp
Original Assignee
PharMetrix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PharMetrix Corp filed Critical PharMetrix Corp
Publication of CN1625404A publication Critical patent/CN1625404A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA03802988XA 2002-01-30 2003-01-30 用于心血管疾病预防或治疗的醛甾酮受体拮抗剂和α－肾上腺素调节剂的组合治疗 Pending CN1625404A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35380102P 2002-01-30 2002-01-30
US60/353,801 2002-01-30

Publications (1)

Publication Number Publication Date
CN1625404A true CN1625404A (zh) 2005-06-08

Family

ID=27663255

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA03802988XA Pending CN1625404A (zh) 2002-01-30 2003-01-30 用于心血管疾病预防或治疗的醛甾酮受体拮抗剂和α－肾上腺素调节剂的组合治疗

Country Status (11)

Country Link
US (1) US20030199483A1 (enExample)
EP (1) EP1469862A2 (enExample)
JP (1) JP2005519918A (enExample)
KR (1) KR20040096540A (enExample)
CN (1) CN1625404A (enExample)
BR (1) BR0307336A (enExample)
CA (1) CA2474845A1 (enExample)
MX (1) MXPA04007472A (enExample)
PL (1) PL371437A1 (enExample)
WO (1) WO2003063846A2 (enExample)
ZA (1) ZA200405437B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100381163C (zh) * 2006-08-29 2008-04-16 陈俊云 一种含利美尼定的药物
CN110141663A (zh) * 2012-10-30 2019-08-20 法奈克斯公司 通过控制血糖水平用于治疗糖尿病及相关病症的组合物、方法以及用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141182A1 (en) 2015-03-03 2016-09-09 Yee Richard W Compositions and methods for treating ocular diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
JP2004501099A (ja) * 2000-05-11 2004-01-15 フアルマシア　コーポレイション アルドステロン頂点位相時の放出のためのアルドステロンアンタゴニスト組成物
ES2265437T3 (es) * 2000-07-27 2007-02-16 Pharmacia Corporation Terapia de combinacion antagonista epoxi-esteroidal de aldosterona y antagonista beta-adrenergico para tratamiento de la insuficiencia cardiaca congestiva.
KR20040080439A (ko) * 2001-12-12 2004-09-18 파마시아 코포레이션 에폭시-스테로이드성 알도스테론 수용체 길항제에 의한안구 질환의 치료 방법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100381163C (zh) * 2006-08-29 2008-04-16 陈俊云 一种含利美尼定的药物
CN110141663A (zh) * 2012-10-30 2019-08-20 法奈克斯公司 通过控制血糖水平用于治疗糖尿病及相关病症的组合物、方法以及用途

Also Published As

Publication number Publication date
EP1469862A2 (en) 2004-10-27
KR20040096540A (ko) 2004-11-16
ZA200405437B (en) 2005-07-08
WO2003063846A2 (en) 2003-08-07
US20030199483A1 (en) 2003-10-23
BR0307336A (pt) 2004-12-07
PL371437A1 (en) 2005-06-13
CA2474845A1 (en) 2003-08-07
WO2003063846A3 (en) 2003-12-04
JP2005519918A (ja) 2005-07-07
MXPA04007472A (es) 2004-11-10

Similar Documents

Publication Publication Date Title
CN1330556A (zh) 血管紧张肽－转化酶抑制剂和醛固酮拮抗剂用于降低心血管疾病的发病率和死亡率的联合疗法
CN1431902A (zh) 抗高血压剂与抗血管生成剂的治疗组合物
US9216221B2 (en) Medicament and method of diagnosis for treating subclinical Cushing's syndrome
KR20180052120A (ko) Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
US20030220312A1 (en) Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
JP2007525440A (ja) アルドステロン受容体アンタゴニストおよび抗糖尿病剤の組合せ
CN1547473A (zh) 预防由抗精神病药物引起的体重增加的方法
CA3038875A1 (en) Treatment of prostate cancer
US20040214804A1 (en) Combination of an aldosterone receptor antagonist and an anti-obesity agent
KR20180096803A (ko) 이소성 쿠싱 증후군의 감별 진단
CN109311898A (zh) [8-(苯基磺酰基)-3,8-二氮杂双环[3.2.1]辛-3-基](1h-1,2,3-三唑-4-基)甲酮
JP7526783B2 (ja) 癌を処置する方法
CN1455667A (zh) 醛固酮拮抗剂在治疗或预防醛固酮介导的致病作用中的用途
CN1625404A (zh) 用于心血管疾病预防或治疗的醛甾酮受体拮抗剂和α－肾上腺素调节剂的组合治疗
CN1642557A (zh) 醛固酮受体拮抗剂与烟酸或烟酸衍生物的组合
HK1073783A (en) Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
CN1642556A (zh) 醛固酮受体拮抗剂与胆汁酸多价螯合剂的联合
TW201206432A (en) Association of xanthine oxidase inhibitors and angiotensin II receptor antagonists and use thereof
AU2017249459A1 (en) Treatment of renal cell carcinoma with lenvatinib and everolimus
US20190142819A1 (en) Treatment of renal cell carcinoma with lenvatinib and everolimus
CN1625412A (zh) 预防或治疗心血管疾病的醛甾酮拮抗剂和非－甾族抗炎剂的组合疗法
AU2003214938A1 (en) Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
CN1499971A (zh) 芳基乙烯磺酰胺衍生物的新用途
CN101243103B (zh) 高血压症治疗剂
JP2005519918A5 (enExample)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1073783

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1073783

Country of ref document: HK